Clinical Trial Supply Forum Blog

As the clinical trial landscape continues to evolve at an unprecedented pace, Pharma IQ delves into the most significant trends shaping the industry in 2024. From the seismic shifts brought about by the pandemic to the rapid technological advancements transforming supply chains, the 2024 Clinical Trial Supply Industry Trends Report, recently released by Pharma IQ, offers an in-depth exploration of the forces driving change across the clinical trial supply spectrum. In this post, we take a look at some of the trends discussed in the report and understand how you can navigate the complexities of today's clinical trial supply industry.

As Pharma IQ is busy preparing for the 2024 Clinical Trial Supply Forum, we wanted to look back at some of the key insights shared at last year’s event. Speakers at the 2023 event underscored the industry's pivot from pandemic-induced reactive strategies to forward-looking, proactive solutions. With a lens on digitalisation, patient-centricity, sustainability, and the burgeoning role of AI, the forum charted a course for future success in clinical trial supply management. We’ve distilled the wisdom from the 2023 speakers and delegates into ten critical dos and don'ts, to provide a simple checklist for navigating the intricacies of clinical trial supply in an era of rapid transformation:

With the increasing complexity and global scale of trials, the need for a supply strategy that is not only robust but also flexible and adaptable has become paramount. In response to these challenges, Pharma IQ has been working on developing a framework that can be used to support clinical trial supply professionals across the industry: "A Step-by-Step Guide to Building a Clinical Trial Supply Strategy."

Ahead of the Clinical Trial Supply Forum 2022, we spoke to Luiz Barberini, Head of External Manufacturing & Supply – LATAM at Bayer about the key challenges confronting the supply chain, approaches to solving these challenges, the biggest opportunities and how to drive the future of biopharmaceutical supply.

Pharma IQ wanted to analyse this, along with how the industry's challenges have changed within the past 12 months with our survey "Global Clinical Trial Logistics 2019" - the results of which have just been published here.

Pharma Logistics IQ sat down with Paul O'Connor, Global Vice President Quality, Almac, to discuss the potential effects of Brexit on the industry and how ALMAC is preparing for these changes.

In the clinical trial supply market there is continued pressure on the pharmaceutical industry to optimise the clinical supply process from end to end. With this, it is clear that the need for lean process development continues to drive clinical supply experts in this marketplace.

This year we return for the 9^th annual Clinical Trial Supply Forum as we focus on the theme of LEAN. GLOBAL. END TO END.